45 results on '"Stanic K"'
Search Results
2. Survival of lung adenocarcinoma patients with uncommon EGFR mutations in routine clinical practice in Slovenia: 170P
- Author
-
Stanic, K. and Hitij, Turnsek N.
- Published
- 2016
- Full Text
- View/download PDF
3. PD-L1 expression as prognostic factor for survival after chemoradiotherapy of locally advanced NSCLC: 118P
- Author
-
Vrankar, M., Kern, I., and Stanic, K.
- Published
- 2016
- Full Text
- View/download PDF
4. Flow-cytophotometric DNA Measurements for Monitoring and Planning Chemotherapy in Anaplastic Thyroid Carcinoma
- Author
-
Auersperg, M., Us-Krašovec, M., Bešič, N., Pogačnik, A., Stanič, K., Jezeršek, B., Pimpl, Wolfgang, editor, Galvan, Günther, editor, Kogelnik, H. Dieter, editor, Manfreda, Dieter, editor, Niederle, Bruno, editor, Schlag, Peter, editor, and Waclawiczek, Hans-Werner, editor
- Published
- 1993
- Full Text
- View/download PDF
5. 1181P The impact of dosimetric parameters on pneumonitis in patients with stage III non-small cell lung cancer during maintenance treatment with durvalumab after chemoradiotherapy
- Author
-
Vrankar, M., primary, But-Hadzic, J., additional, Stanic, K., additional, Ciric, E., additional, Jelercic, S., additional, and Vodusek, A.L., additional
- Published
- 2021
- Full Text
- View/download PDF
6. Cellular and Molecular Probing of Intact Human Organs.
- Author
-
Wolf E., Lipfert J., Puelles V.G., Bechmann I., Erturk A., Zhao S., Todorov M.I., Cai R., Maskari R.A., Steinke H., Kemter E., Mai H., Rong Z., Warmer M., Stanic K., Schoppe O., Paetzold J.C., Gesierich B., Wong M.N., Huber T.B., Duering M., Bruns O.T., Menze B., Wolf E., Lipfert J., Puelles V.G., Bechmann I., Erturk A., Zhao S., Todorov M.I., Cai R., Maskari R.A., Steinke H., Kemter E., Mai H., Rong Z., Warmer M., Stanic K., Schoppe O., Paetzold J.C., Gesierich B., Wong M.N., Huber T.B., Duering M., Bruns O.T., and Menze B.
- Abstract
Zhao et al. present an approach for intact human organ mapping that uses a new tissue permeabilization method to clear and deeply label whole organs followed by light-sheet microscopy imaging and a deep learning-based pipeline for 3D reconstruction and data analysis. Optical tissue transparency permits scalable cellular and molecular investigation of complex tissues in 3D. Adult human organs are particularly challenging to render transparent because of the accumulation of dense and sturdy molecules in decades-aged tissues. To overcome these challenges, we developed SHANEL, a method based on a new tissue permeabilization approach to clear and label stiff human organs. We used SHANEL to render the intact adult human brain and kidney transparent and perform 3D histology with antibodies and dyes in centimeters-depth. Thereby, we revealed structural details of the intact human eye, human thyroid, human kidney, and transgenic pig pancreas at the cellular resolution. Furthermore, we developed a deep learning pipeline to analyze millions of cells in cleared human brain tissues within hours with standard lab computers. Overall, SHANEL is a robust and unbiased technology to chart the cellular and molecular architecture of large intact mammalian organs.Copyright © 2020 Elsevier Inc.
- Published
- 2020
7. Innovative approaches for the study of biodiversity and water quality assessment in the Alpine region: the Interreg Alpine Space project Eco-Alpswater
- Author
-
Nico Salmaso, Baudoin, J. M., Bernabei, S., Adriano Boscaini, Bouchez, A., Capelli, C., leonardo cerasino, Dobrovolny, S., Domaizon, I., Claudio Donati, Elersek, T., Franzini, G., Greco, C., Hufnagl, P., Krivograd Klemenčič, A., Kurmayer, R., Lepori, F., Logez, M., Mischke, U., Massimo Pindo, Remec-Rekar, S., Schaumburg, J., Schubert, M., Stanic, K., Tomassetti, P., Vogelmann, C., Wanzenböck, J., and Zampieri, C.
- Subjects
Next Generation Monitoring ,High-throughput sequencing ,Settore BIO/07 - ECOLOGIA ,Eco-AlpsWater - Published
- 2019
8. Local control and survival after stereotactic body radiation therapy of early-stage lung cancer patients in Slovenia
- Author
-
Stanic Karmen, But-Hadzic Jasna, Zagar Jan, and Vrankar Martina
- Subjects
stereotactic body radiotherapy (sbrt) ,early-stage lung cancer ,lung cancer ,local control ,survival ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Stereotactic body radiation therapy (SBRT) precisely and non-invasively delivers ablative radiation dose to tumors in early-stage lung cancer patients who are not candidates for surgery or refuse it. The aim of research was to evaluate local control, overall survival (OS), local progression free survival (LPFS), distant metastases free survival (DMFS), disease free survival (DFS) and toxicity in early-stage lung cancer patients treated with SBRT in a single tertiary cancer centre.
- Published
- 2023
- Full Text
- View/download PDF
9. Comparison of Two Radiotherapy Regimens for Metastatic Spinal Cord Compression: Subgroup Analyses from a Randomized Trial
- Author
-
Rades D, Conde-Moreno AJ, Cacicedo J, Šegedin B, Stanic K, Metz M, Rudat V, and Schild SE
- Subjects
subgroup analyses ,randomized trial ,Metastatic spinal cord compression ,survival prognosis ,treatment outcomes ,radiotherapy - Abstract
Background/Aim: According to our randomized trial, 5x4Gy was comparable to 10x3Gy for metastatic spinal cord compression. Since it remained unclear whether findings applied to poor and intermediate prognoses patients, subgroup analyses were performed. Patients and Methods: In patients with poor prognoses, 58 received 5x4Gy, 53 received 10x3Gy. In intermediate-prognoses patients, numbers were 43 and 49. Results: In patients with poor prognoses, 1-month overall response (OR) was 85% after 5x4Gy and 10x3Gy (p=0.99), improvement 38% vs. 42%, ambulatory status 60% vs. 64% (p=0.83), 6-month local progression-free survival (LPFS) 75% vs. 69% (p=0.74) and 6-month overall survival (OS) 26% vs. 19% (p=0.43). In patients with intermediate prognoses, 1-month OR was 89% after 5x4Gy and 93% after 10x3Gy (p=0.85), improvement 39% vs. 45%, ambulatory status 84% vs. 82% (p=0.90), 6-month LPFS 79% vs. 92% (p=0.17) and 6-months OS 65% vs. 58% (p=0.65). Conclusion: 5x4Gy was not significantly inferior to 10x3Gy in both subgroups.
- Published
- 2018
10. 1x8 Gy versus 5x4 Gy for metastatic epidural spinal cord compression: a matched-pair study of three prognostic patient subgroups
- Author
-
Rades D, Conde-Moreno AJ, Cacicedo J, Veninga T, Segedin B, Stanic K, Rudat V, and Schild SE
- Abstract
Background: This study provides separate comparisons of 1 x 8 Gy to 5 x 4 Gy for metastatic epidural spinal cord compression (MESCC) in patients with poor, intermediate and favorable survival prognoses. Methods: Patients receiving 1 x 8 Gy were matched to patients receiving 5 x 4 Gy for age, gender, performance status, tumor type, involved vertebrae, other bone metastases, visceral metastases, interval between tumor diagnosis and MESCC, ambulatory status and time developing motor deficits. From a study including patients with poor (N = 156) or intermediate (N = 86) survival prognoses, subgroup analyses were performed. Furthermore, 232 new patients with favorable prognoses matched the same way were included. Results: In poor prognoses patients, 6-month survival rates were 10% after 1 x 8 Gy and 6% after 5 x 4 Gy (p = 0.38); in-field reRT rates in few patients alive at 6 months were 15 and 2% (p = 0.16). In intermediate prognoses patients, 6-month survival rates were 49% after 1 x 8 Gy and 58% after 5 x 4 Gy (p = 0.30). ReRT rates at 6 months were 23 and 13% (p = 0.25). In favorable prognoses patients, 6-month survival rates were 89% after 1 x 8 Gy and 91% after 5 x 4 Gy. ReRT rates at 6 months were 14 and 3% (p = 0.007). In no subgroup, RT regimen had a significant impact on motor function. Conclusions: Since in patients with poor prognoses, outcomes after 1x8 Gy and 5x4 Gy were not significantly different, 1 x 8 Gy may be an option. In patients with intermediate prognoses, a trend was found in favor of 5 x 4 Gy. In patients with favorable prognoses, need for in-field reRT was greater after 1 x 8 Gy.
- Published
- 2018
11. The impact of the new TNM classification on survival of patients in stage III non-small cell lung cancer
- Author
-
Vrankar, M., primary and Stanic, K., additional
- Published
- 2018
- Full Text
- View/download PDF
12. PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy
- Author
-
VRANKAR, M., primary, ZWITTER, M., additional, KERN, I., additional, and STANIC, K., additional
- Published
- 2018
- Full Text
- View/download PDF
13. EP1.12-13 Consolidation Radiotherapy in Extended Disease Small Cell Lung Cancer: Single Center Experience
- Author
-
Stanič, K., But-Hadžić, J., and Vrankar, M.
- Published
- 2019
- Full Text
- View/download PDF
14. 118P: PD-L1 expression as prognostic factor for survival after chemoradiotherapy of locally advanced NSCLC
- Author
-
Vrankar, M., primary, Kern, I., additional, and Stanic, K., additional
- Published
- 2016
- Full Text
- View/download PDF
15. 170P: Survival of lung adenocarcinoma patients with uncommon EGFR mutations in routine clinical practice in Slovenia
- Author
-
Stanic, K., primary and Hitij, N. Turnsek, additional
- Published
- 2016
- Full Text
- View/download PDF
16. Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience
- Author
-
Vrankar Martina, Stanic Karmen, Jelercic Stasa, Ciric Eva, Vodusek Ana Lina, and But-Hadzic Jasna
- Subjects
non-small cell lung cancer ,stage iii ,chemoradiotherapy ,durvalumab ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Chemoradiotherapy (ChT-RT) followed by 12-month durvalumab is the new standard treatment for unresectable stage III non-small cell lung cancer. Survival data for patients from everyday routine clinical practice is scarce, as well as potential impact on treatment efficacy of sequential or concomitant chemotherapy and the usage of gemcitabine.
- Published
- 2021
- Full Text
- View/download PDF
17. 1366P - The impact of the new TNM classification on survival of patients in stage III non-small cell lung cancer
- Author
-
Vrankar, M. and Stanic, K.
- Published
- 2018
- Full Text
- View/download PDF
18. Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern Europe
- Author
-
Zemanova Milada, Jakopovic Marko, Stanic Karmen, Łazar-Poniatowska Małgorzata, Vrankar Martina, Rusu Petronela, Ciuleanu Tudor, Radosavljevic Davorin, Bogos Krisztina, and Nawrocki Sergiusz
- Subjects
stage iii non-small cell lung cancer ,treatment patterns ,delphi method ,quality of care ,expert panel ,real-world evidence ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
The aim of this project was to collect real-world evidence and describe treatment patterns for stage III non-small cell lung cancer in Central and Eastern Europe. Based on real-world evidence, an expert opinion was developed, and the unmet needs and quality indicators were identified.
- Published
- 2020
- Full Text
- View/download PDF
19. Consolidation radiotherapy for patients with extended disease small cell lung cancer in a single tertiary institution: impact of dose and perspectives in the era of immunotherapy
- Author
-
Stanic Karmen, Vrankar Martina, and But-Hadzic Jasna
- Subjects
small cell lung cancer ,ed-sclc ,radiotherapy ,consolidation radiotherapy ,immunotherapy ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Consolidation radiotherapy (cRT) in extended disease small cell lung cancer (ED-SCLC) showed improved 2-year overall survival in patients who responded to chemotherapy (ChT) in CREST trial, however results of two meta - analysis were contradictive. Recently, immunotherapy was introduced to the treatment of ED-SCLC, making the role of cRT even more unclear. The aim of our study was to access if consolidation thoracic irradiation improves survival of ED-SCLC patients treated in a routine clinical practice and to study the impact of cRT dose on survival. We also discuss the future role of cRT in the era of immunotherapy.
- Published
- 2020
- Full Text
- View/download PDF
20. The Serbian pension system in transition: A silent break with Bismarck
- Author
-
Matković Gordana and Stanić Katarina
- Subjects
bismarck ,beveridge ,silent break ,net replacement rate ,pension variation ,Economic growth, development, planning ,HD72-88 - Abstract
The pension system in Serbia was set up as Bismarckian earnings related system almost one hundred years ago. At the outset of the transition process at the beginning of 21st Century, the pension system underwent bold reforms. Despite suggestions from the World Bank to adopt a three-pillar system that would involve a break with the Bismarckian heritage, reforms concentrated on parametric adjustments that strengthened the link between previous earnings and pension benefits. However, as this paper shows, the Bismarckian earnings-related system has subsequently been silently challenged. On the basis of an analysis of the current and perspective replacement rates for various earning levels and pension variation indicators, we show how the contributions/ benefit link has been undermined. These policy changes have not been defined or understood as a new strategic course of action, nor have the strategic options been debated and analysed. These silent reforms have seemed to be a “quick and easy” solution to tackle high public expenditures and deficits without understanding their implications, and that breaking up with Bismarck implies significant transition costs.
- Published
- 2020
- Full Text
- View/download PDF
21. SCO-spondin from embryonic cerebrospinal fluid is required for neurogenesis during early brain development
- Author
-
Vera, A., primary, Stanic, K., additional, Montecinos, H., additional, Torrejón, M., additional, Marcellini, S., additional, and Caprile, T., additional
- Published
- 2013
- Full Text
- View/download PDF
22. Incorporation of EGFR mutation status into M descriptor of new TNM classification influences survival curves in non-small cell lung cancer patients
- Author
-
Stanic Karmen, Turnsek Nina, and Vrankar Martina
- Subjects
egfr mutations ,non-small cell lung cancer ,survival ,metastases ,tnm ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
The 8th edition of tumor node metastasis (TNM) staging system for lung cancer introduced a revision of M descriptor. The limitation of new classification to predict prognosis is its focus on anatomical extent of the disease only. Information on molecular status of the tumor significantly influences treatment response and survival; however, data addressing this issue is scarce. This report points to the impact of epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC) patients on survival in view of new M descriptors of TNM classification system.
- Published
- 2019
- Full Text
- View/download PDF
23. Is postmastectomy radiotherapy really needed in breast cancer patients with many positive axillary lymph nodes?
- Author
-
Marinko Tanja and Stanic Karmen
- Subjects
breast cancer ,postmastectomy radiotherapy ,positive axillary lymph nodes ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Postmastectomy radiotherapy (PMRT) improves survival by eliminating potential occult lesions in the chest wall and lymphatic drainage area. Meta-analysis has shown that PMRT reduces mortality and local recurrence of patients with node positive breast cancer, but there is no specific data about the effectiveness of PMRT in a subgroup of patients with a high number of positive axillary lymph nodes (PALN). The aim of the study was to analyse the impact of the number of PALN on local and distant metastasis occurrence, overall survival (OS) and distant metastases free survival (DMFS) in patients treated with PMRT.
- Published
- 2018
- Full Text
- View/download PDF
24. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy
- Author
-
Vrankar Martina and Stanic Karmen
- Subjects
locally advanced nsclc ,survival ,immunotherapy ,pd-l1 expression ,chemoradiotherapy ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Standard treatment for patients with inoperable locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT). Five-year overall survival rates range between 15 and 25%, while long term survival data are rarely reported.
- Published
- 2018
- Full Text
- View/download PDF
25. Understanding the increase in the number of childbirth-related leave beneficiaries in Serbia
- Author
-
Stanić Katarina and Matković Gordana
- Subjects
childbirth-related leave ,special child-care leave ,maternity/parental beneficiaries ,public expenditures on maternity/parental leave ,lack of flexibility of childbirth-related leave system ,Demography. Population. Vital events ,HB848-3697 - Abstract
Over the past number of years, the public expenditures for childbirth-related leave benefits have more than doubled – in 2015 amounted to 0.7% GDP in relation to 0.3% GDP in 2002. This increase can mainly be attributed to the increased number of beneficiaries that grew consistently from 24 thousand in 2002 up to 40 thousand in 2015, despite the fact that the annual number of live births has been almost continually decreasing and the registered employment has dropped by almost 20 per cent in the observed period. One of the clear reasons explaining part of this increase is the extension of 3+ order of birth leaves in 2006, from one to two years, which can explain the increase of around 3.5 thousand of beneficiaries. Another reason is high number of beneficiaries using special child-care leave meant for parents with children with disabilities, but which, in reality, is very often used simply as the extension of parental leave. The average number of special child-care leave beneficiaries in the second half of 2015 amounted to 2.8 thousand. When these two effects are taken into account, we still notice significant increase of beneficiaries of around 10 thousand in the observed period. Fictitious employment during the pregnancy can explain this increase to some extent. Available data unambiguously show that a number of women formally employing during the second and third trimester of pregnancy has increased from 800 in 2002 to almost 3.5 thousand monthly average in the second half of 2015. There are two flaws of the childbirth-related leave programme in Serbia, which together lead to the constant increase of the number of beneficiaries. First is the lack of flexibility of the programme, both in terms of eligibility for acquiring the right as well as in terms of flexibility in use. Maternity/parental leave benefit may acquire only those in „standard employment” i.e. employed under employment contract (and entrepreneurs) while other type of contracts is not eligible. Second problem is the loophole in the benefit calculation method and the inadequate special child-care acquiring procedure which brings about the inclusion error. This results in the increase of generosity of the program, in a selective way, which in turn jeopardizes the financial sustainability of the programme as a whole. The reform of the childbirth-related leave program should progress in two directions. First is the change of the benefit calculation method extending the calculation base period so that it disables misuse and inclusion error; enabling the right to those with flexible/non-standard employment; and tightening the eligibility criteria for special-care leave. Second array of reform should tackle the flexibility in use, allowing options such as taking a leave on part-time basis or taking longer periods of leave with lower benefits.
- Published
- 2017
- Full Text
- View/download PDF
26. Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations
- Author
-
Zwitter Matjaz, Stanic Karmen, Rajer Mirjana, Kern Izidor, Vrankar Martina, Edelbaher Natalija, and Kovac Viljem
- Subjects
non-small cell lung cancer ,egfr activating mutations ,gemcitabine ,cisplatin ,erlotinib ,intercalated therapy ,metabolic response ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Background. Pharmaco-dynamic separation of cytotoxic and targeted drugs might avoid their mutual antagonistic effect in the treatment of advanced non-small cell lung cancer (NSCLC).
- Published
- 2014
- Full Text
- View/download PDF
27. Family/children cash benefits in Serbia: The analysis and policy recommendations
- Author
-
Matković Gordana, Mijatović Boško, and Stanić Katarina
- Subjects
financial social assistance ,child allowance ,maternity/parental benefits ,birth grant ,Demography. Population. Vital events ,HB848-3697 - Abstract
Around 400 thousand children in Serbia are covered with cash-benefits targeting poor children representing 31.7% of the total number of children in 2011. Additionally, around 60 thousand families receive birth grants that is more than 90% of the newly born. When it comes to child-birth related leaves, there were around 37 thousand beneficiaries in 2012. This means that around 50% of the newly born children’s parents are covered with maternity/parental leave, while the coverage of employed mothers is almost full. Coverage of the poor children, particularly by the financial social assistance (FSA), can be considered inadequate. When it comes to targeting (vertical efficiency), FSA is targeted quite well, while there is scope for improvement of the inclusion error within the child-allowance program. When the adequacy of cash benefits targeting poor children is analyzed from the perspective of meeting the basic needs, then the amount is at the verge of being acceptable and differs for different kinds of families - single parent and families with very young children (0-2) being better off. However, when compared to the minimum wage, the cumulative amount of FSA and child allowance is lower only for one- child families. Total expenditures for cash-benefits connected to children amount to 1.4%of GDP - 1.21% being related to ESSPROS family/children function and 0.18% for the FSA for families with children. When compared to the EU, the total expenditure is below the EU average, with the birth related expenditures being higher and child allowance lower than the EU average. The first group of recommendations for cash benefits aimed at families with children relate to the improvement of adequacy and coverage of benefits aiming at poverty reduction, while respecting budget constraints. The increase of benefits for children above 14 years old - increase of child allowance or/and assigning higher weights (0.5 instead of 0.3) for the FSA’s equivalence scale, seems the least controversial measure. When it comes to child allowance benefits, comparative analysis shows that it is more important to increase the coverage rather than to increase the amount. Elimination of requirement for the parents to be covered with health insurance, allowing child allowance right for 4 children (instead of the first 4 children in the family) and relaxation of property criteria could act toward this end. Both from the perspective of improving the coverage and better targeting, the cadastral revenue as eligibility criteria for agricultural households should be replaced with some more realistic criteria. When it comes to child-birth related leaves, due to evidence of misuse of maternity/parental leave benefit by formal employment registration just a few months before child’s birth, one of the recommendations is to prolong the benefit calculation period, while at the same time extending the coverage for women with flexible jobs. Also, the introduction of flexible arrangements for parental leave, such as a choosing different combinations of benefit level and leave duration, part-time work and similar. Speaking of birth grants, there are advantages of introducing one-off payment instead of payment in installments, which actually implies returning to the model before changes were introduced in 2005. In addition, indexation of property threshold should be introduced. Finally, there is a need for benefits’ consolidation and simplification of administrative procedures.
- Published
- 2014
- Full Text
- View/download PDF
28. Distinct molecular profiles of skull bone marrow in health and neurological disorders.
- Author
-
Kolabas ZI, Kuemmerle LB, Perneczky R, Förstera B, Ulukaya S, Ali M, Kapoor S, Bartos LM, Büttner M, Caliskan OS, Rong Z, Mai H, Höher L, Jeridi D, Molbay M, Khalin I, Deligiannis IK, Negwer M, Roberts K, Simats A, Carofiglio O, Todorov MI, Horvath I, Ozturk F, Hummel S, Biechele G, Zatcepin A, Unterrainer M, Gnörich J, Roodselaar J, Shrouder J, Khosravani P, Tast B, Richter L, Díaz-Marugán L, Kaltenecker D, Lux L, Chen Y, Zhao S, Rauchmann BS, Sterr M, Kunze I, Stanic K, Kan VWY, Besson-Girard S, Katzdobler S, Palleis C, Schädler J, Paetzold JC, Liebscher S, Hauser AE, Gokce O, Lickert H, Steinke H, Benakis C, Braun C, Martinez-Jimenez CP, Buerger K, Albert NL, Höglinger G, Levin J, Haass C, Kopczak A, Dichgans M, Havla J, Kümpfel T, Kerschensteiner M, Schifferer M, Simons M, Liesz A, Krahmer N, Bayraktar OA, Franzmeier N, Plesnila N, Erener S, Puelles VG, Delbridge C, Bhatia HS, Hellal F, Elsner M, Bechmann I, Ondruschka B, Brendel M, Theis FJ, and Erturk A
- Subjects
- Animals, Humans, Mice, Brain diagnostic imaging, Brain metabolism, Carrier Proteins metabolism, Positron-Emission Tomography methods, Receptors, GABA metabolism, Bone Marrow metabolism, Nervous System Diseases metabolism, Nervous System Diseases pathology, Skull cytology, Skull diagnostic imaging
- Abstract
The bone marrow in the skull is important for shaping immune responses in the brain and meninges, but its molecular makeup among bones and relevance in human diseases remain unclear. Here, we show that the mouse skull has the most distinct transcriptomic profile compared with other bones in states of health and injury, characterized by a late-stage neutrophil phenotype. In humans, proteome analysis reveals that the skull marrow is the most distinct, with differentially expressed neutrophil-related pathways and a unique synaptic protein signature. 3D imaging demonstrates the structural and cellular details of human skull-meninges connections (SMCs) compared with veins. Last, using translocator protein positron emission tomography (TSPO-PET) imaging, we show that the skull bone marrow reflects inflammatory brain responses with a disease-specific spatial distribution in patients with various neurological disorders. The unique molecular profile and anatomical and functional connections of the skull show its potential as a site for diagnosing, monitoring, and treating brain diseases., Competing Interests: Declaration of interests M. Brendel received speaker honoraria from GE healthcare, Roche, and Life Molecular Imaging and is an advisor of Life Molecular Imaging. J.H. reports personal fees, research grants, and non-financial support from Merck, Bayer, Novartis, Roche, Biogen, and Celgene and non-financial support of the Guthy-Jackson Charitable Foundation—none in relation to this study. C.P. is inventor in a patent “Oral Phenylbutyrate for Treatment of Human 4-Repeat Tauopathies” (EP 23 156 122.6) filed by LMU Munich. T.K. has received speaker honoraria and/or personal fees for advisory boards from Bayer Healthcare, Teva Pharma, Merck, Novartis, Sanofi/Genzyme, Roche, and Biogen as well as grant support from Novartis and Chugai Pharma—none in relation to this study. M.K. has been on advisory boards for Biogen, medDay Pharmaceuticals, Novartis, and Sanofi; has received grant support from Sanofi and Biogen; and has received speaker fees from Abbvie, Almirall, Biogen, medDay Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi, and Teva—none in relation to this study. R.P. has received speaker honoraria, research support, and consultancy fees from Janssen, Eli Lilly, Biogen, Wilmar Schwabe, Takeda, Novo Nordisk, and Bayer Healthcare. N.K. has received speaker honoraria from Novartis and Regeneron and research grants from Regeneron—none in relationship to this study. M.I.T., H.S.B., M.N., and A.E. received speaker honoraria from Miltenyi Biotec—none in relation to this study. A.E. is co-founder of Deep Piction and 1X1 Biotech., (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
29. Neuroimmune cardiovascular interfaces control atherosclerosis.
- Author
-
Mohanta SK, Peng L, Li Y, Lu S, Sun T, Carnevale L, Perrotta M, Ma Z, Förstera B, Stanic K, Zhang C, Zhang X, Szczepaniak P, Bianchini M, Saeed BR, Carnevale R, Hu D, Nosalski R, Pallante F, Beer M, Santovito D, Ertürk A, Mettenleiter TC, Klupp BG, Megens RTA, Steffens S, Pelisek J, Eckstein HH, Kleemann R, Habenicht L, Mallat Z, Michel JB, Bernhagen J, Dichgans M, D'Agostino G, Guzik TJ, Olofsson PS, Yin C, Weber C, Lembo G, Carnevale D, and Habenicht AJR
- Subjects
- Animals, Disease Progression, Ganglia, Spinal, Ganglia, Sympathetic, Mice, Neurons physiology, Atherosclerosis prevention & control, Plaque, Atherosclerotic prevention & control
- Abstract
Atherosclerotic plaques develop in the inner intimal layer of arteries and can cause heart attacks and strokes
1 . As plaques lack innervation, the effects of neuronal control on atherosclerosis remain unclear. However, the immune system responds to plaques by forming leukocyte infiltrates in the outer connective tissue coat of arteries (the adventitia)2-6 . Here, because the peripheral nervous system uses the adventitia as its principal conduit to reach distant targets7-9 , we postulated that the peripheral nervous system may directly interact with diseased arteries. Unexpectedly, widespread neuroimmune cardiovascular interfaces (NICIs) arose in mouse and human atherosclerosis-diseased adventitia segments showed expanded axon networks, including growth cones at axon endings near immune cells and media smooth muscle cells. Mouse NICIs established a structural artery-brain circuit (ABC): abdominal adventitia nociceptive afferents10-14 entered the central nervous system through spinal cord T6 -T13 dorsal root ganglia and were traced to higher brain regions, including the parabrachial and central amygdala neurons; and sympathetic efferent neurons projected from medullary and hypothalamic neurons to the adventitia through spinal intermediolateral neurons and both coeliac and sympathetic chain ganglia. Moreover, ABC peripheral nervous system components were activated: splenic sympathetic and coeliac vagus nerve activities increased in parallel to disease progression, whereas coeliac ganglionectomy led to the disintegration of adventitial NICIs, reduced disease progression and enhanced plaque stability. Thus, the peripheral nervous system uses NICIs to assemble a structural ABC, and therapeutic intervention in the ABC attenuates atherosclerosis., (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)- Published
- 2022
- Full Text
- View/download PDF
30. Tissue Clearing Approaches in Atherosclerosis.
- Author
-
Sun T, Li Y, Förstera B, Stanic K, Lu S, Steffens S, Yin C, Ertürk A, Megens RTA, Weber C, Habenicht A, and Mohanta SK
- Subjects
- Arteries, Humans, Microscopy, Atherosclerosis, Imaging, Three-Dimensional methods
- Abstract
Recent advances in cardiovascular research have led to a more comprehensive understanding of molecular mechanisms of atherosclerosis. It has become apparent that the disease involves three layers of the arterial wall: the intima, the media, and a connective tissue coat termed the adventitia. It is also now appreciated that arteries are surrounded by adipose and neuronal tissues. In addition, adjacent to and within the adventitia, arteries are embedded in a loose connective tissue containing blood vessels (vasa vasora) and lymph vessels, artery-draining lymph nodes and components of the peripheral nervous system, including periarterial nerves and ganglia. During atherogenesis, each of these tissues undergoes marked structural and cellular alterations. We propose that a better understanding of these cell-cell and cell-tissue interactions may considerably advance our understanding of cardiovascular disease pathogenesis. Methods to acquire subcellular optical access to the intact tissues surrounding healthy and diseased arteries are urgently needed to achieve these aims. Tissue clearing is a landmark next-generation, three-dimensional (3D) microscopy technique that allows to image large-scale hitherto inaccessible intact deep tissue compartments. It allows for detailed reconstructions of arteries by a combination of labelling, clearing, advanced microscopies and other imaging and data-analysis tools. Here, we describe two distinct tissue clearing protocols; solvent-based modified three-dimensional imaging of solvent-cleared organs (3DISCO) clearing and another using aqueous-based 2,2'-thiodiethanol (TDE) clearing, both of which complement each other., (© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
31. Incidental Detection of Factor XII Deficiency Following Coronary Artery Bypass Grafting.
- Author
-
Vuckovic J, Zdravkovic R, Babovic Stanic K, Majin M, and Velicki L
- Subjects
- Coronary Artery Bypass, Heparin, Humans, Factor XII Deficiency
- Published
- 2021
- Full Text
- View/download PDF
32. Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy.
- Author
-
Vrankar M, Kern I, and Stanic K
- Subjects
- Aged, C-Reactive Protein analysis, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung pathology, Female, Humans, Lung Neoplasms mortality, Lung Neoplasms pathology, Male, Middle Aged, Neoplasm Staging, Prognosis, B7-H1 Antigen analysis, Carcinoma, Non-Small-Cell Lung therapy, Chemoradiotherapy, Lung Neoplasms therapy
- Abstract
Background: Expression of PD-L1 is the most investigated predictor of benefit from immune checkpoint blockade in advanced NSCLC but little is known about the association of PD-L1 expression and clinicopathological parameters of patients with unresectable stage III NSCLC., Methods: National registry data was searched for medical records of consecutive inoperable stage III NSCLC patients treated with ChT and RT from January 2012 to December 2017. Totally 249 patients were identified that met inclusion criteria and of those 117 patients had sufficient tissue for PD-L1 immunohistochemical staining., Results: Eighty patients (68.4%) expressed PD-L1 of ≥ 1% and 29.9% of more than 50%. Median PFS was 15.9 months in PD-L1 negative patients and 16.1 months in patients with PD-L1 expression ≥ 1% (p = 0.696). Median OS in PD-L1 negative patients was 29.9 months compared to 28.5 months in patients with PD-L1 expression ≥ % (p = 0.888). There was no difference in median OS in patients with high PD-L1 expression (≥ 50%) with 29.8 months compared to 29.9 months in those with low (1-49%) or no PD-L1 expression (p = 0.694). We found that patients who received a total dose of 60 Gy or more had significantly better median OS (32 months vs. 17.5 months, p < 0.001) as well as patients with PS 0 (33.2 vs. 20.3 months, p = 0.005)., Conclusions: In our patients PD-L1 expression had no prognostic value regarding PFS and OS. Patients with good performance status and those who received a total radiation dose of more than 60 Gy had significantly better mOS.
- Published
- 2020
- Full Text
- View/download PDF
33. Author Correction: The Reprimo gene family member, reprimo-like (rprml), is required for blood development in embryonic zebrafish.
- Author
-
Stanic K, Reig G, Figueroa RJ, Retamal PA, Wichmann IA, Opazo JC, Owen GI, Corvalán AH, Concha ML, and Amigo JD
- Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Published
- 2020
- Full Text
- View/download PDF
34. Cellular and Molecular Probing of Intact Human Organs.
- Author
-
Zhao S, Todorov MI, Cai R, -Maskari RA, Steinke H, Kemter E, Mai H, Rong Z, Warmer M, Stanic K, Schoppe O, Paetzold JC, Gesierich B, Wong MN, Huber TB, Duering M, Bruns OT, Menze B, Lipfert J, Puelles VG, Wolf E, Bechmann I, and Ertürk A
- Subjects
- Aged, 80 and over, Animals, Brain diagnostic imaging, Eye diagnostic imaging, Female, Humans, Imaging, Three-Dimensional standards, Kidney diagnostic imaging, Limit of Detection, Male, Mice, Middle Aged, Optical Imaging standards, Pancreas diagnostic imaging, Staining and Labeling standards, Swine, Thyroid Gland diagnostic imaging, Deep Learning, Imaging, Three-Dimensional methods, Optical Imaging methods, Staining and Labeling methods
- Abstract
Optical tissue transparency permits scalable cellular and molecular investigation of complex tissues in 3D. Adult human organs are particularly challenging to render transparent because of the accumulation of dense and sturdy molecules in decades-aged tissues. To overcome these challenges, we developed SHANEL, a method based on a new tissue permeabilization approach to clear and label stiff human organs. We used SHANEL to render the intact adult human brain and kidney transparent and perform 3D histology with antibodies and dyes in centimeters-depth. Thereby, we revealed structural details of the intact human eye, human thyroid, human kidney, and transgenic pig pancreas at the cellular resolution. Furthermore, we developed a deep learning pipeline to analyze millions of cells in cleared human brain tissues within hours with standard lab computers. Overall, SHANEL is a robust and unbiased technology to chart the cellular and molecular architecture of large intact mammalian organs., Competing Interests: Declaration of Interests A.E. has filed a patent on SHANEL technologies described in this study., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
35. The Reprimo gene family member, reprimo-like (rprml), is required for blood development in embryonic zebrafish.
- Author
-
Stanic K, Reig G, Figueroa RJ, Retamal PA, Wichmann IA, Opazo JC, Owen GI, Corvalán AH, Concha ML, and Amigo JD
- Subjects
- Animals, CRISPR-Cas Systems, Cell Cycle Proteins genetics, Embryonic Development, Hematopoiesis, Morpholinos pharmacology, Multigene Family, Zebrafish blood, Zebrafish genetics, Zebrafish Proteins genetics, Hemangioblasts metabolism, Membrane Proteins genetics, Zebrafish embryology
- Abstract
The Reprimo gene family comprises a group of single-exon genes for which their physiological function remains poorly understood. Heretofore, mammalian Reprimo (RPRM) has been described as a putative p53-dependent tumor suppressor gene that functions at the G2/M cell cycle checkpoint. Another family member, Reprimo-like (RPRML), has not yet an established role in physiology or pathology. Importantly, RPRML expression pattern is conserved between zebrafish and human species. Here, using CRISPR-Cas9 and antisense morpholino oligonucleotides, we disrupt the expression of rprml in zebrafish and demonstrate that its loss leads to impaired definitive hematopoiesis. The formation of hemangioblasts and the primitive wave of hematopoiesis occur normally in absence of rprml. Later in development there is a significant reduction in erythroid-myeloid precursors (EMP) at the posterior blood island (PBI) and a significant decline of definitive hematopoietic stem/progenitor cells (HSPCs). Furthermore, loss of rprml also increases the activity of caspase-3 in endothelial cells within the caudal hematopoietic tissue (CHT), the first perivascular niche where HSPCs reside during zebrafish embryonic development. Herein, we report an essential role for rprml during hematovascular development in zebrafish embryos, specifically during the definitive waves of hematopoiesis, indicating for the first time a physiological role for the rprml gene.
- Published
- 2019
- Full Text
- View/download PDF
36. A scoring system to predict local progression-free survival in patients irradiated with 20 Gy in 5 fractions for malignant spinal cord compression.
- Author
-
Rades D, Conde-Moreno AJ, Cacicedo J, Veninga T, Segedin B, Stanic K, and Schild SE
- Subjects
- Aged, Female, Follow-Up Studies, Gamma Rays, Humans, Male, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local radiotherapy, Neoplasms pathology, Neoplasms radiotherapy, Prognosis, Radiotherapy Dosage, Retrospective Studies, Spinal Cord Compression pathology, Spinal Cord Compression radiotherapy, Spinal Cord Neoplasms radiotherapy, Spinal Cord Neoplasms secondary, Survival Rate, Survivors, Neoplasm Recurrence, Local mortality, Neoplasms mortality, Spinal Cord Compression mortality, Spinal Cord Neoplasms mortality
- Abstract
Background: Local progression-free survival (LPFS = stable or improved motor function/resolution of paraplegia during RT without in-field recurrence following RT) is important when treating metastatic spinal cord compression (MSCC). An instrument to estimate LPFS was created to identify patients appropriately treated with short-course RT instead of longer-course RT plus/minus decompressive surgery., Methods: In 686 patients treated with 20 Gy in 5 fractions alone, ten characteristics were retrospectively analyzed for LPFS including age, interval between tumor diagnosis and RT of MSCC, visceral metastases, other bone metastases, primary tumor type, gender, time developing motor deficits, pre-RT gait function, number of vertebrae affected by MSCC, and performance score. Characteristics significantly (p < 0.05) associated with LPFS on multivariate analyses were incorporated in the scoring system. Six-month LPFS rates for significant characteristics were divided by 10, and corresponding points were added., Results: On multivariate analyses, visceral metastases (p < 0.001), tumor type (p = 0.009), time developing motor deficits (p < 0.001) and performance score (p = 0.009) were associated with LPFS and used for the scoring system. Scores for patients ranged between 24 and 35 points. Three groups were designed: 24-28 (A), 29-31 (B) and 32-35 (C) points. Six-month LPFS rates were 46, 69 and 92%, 12-month LPFS rates 46, 63 and 83%. Median survival times were 2 months (61% died within 2 months), 4 months and ≥ 11 months (median not reached)., Conclusions: Most group A patients appeared sub-optimally treated with 20 Gy in 5 fractions. Patients with survival prognoses ≤2 months may be considered for best supportive care or single-fraction RT, those with prognoses ≥3 months for longer-course RT plus/minus upfront decompressive surgery. Many group B and most group C patients achieved long-time LPFS and appeared sufficiently treated with 20 Gy in 5 fractions. However, based on previous data, long-term survivors may benefit from longer-course RT.
- Published
- 2018
- Full Text
- View/download PDF
37. Expression of RPRM/rprm in the Olfactory System of Embryonic Zebrafish ( Danio rerio ).
- Author
-
Stanic K, Quiroz A, Lemus CG, Wichmann IA, Corvalán AH, Owen GI, Opazo JC, Concha ML, and Amigo JD
- Abstract
The Reprimo ( RPRM ) family is composed of highly conserved single-exon genes. The expression pattern of this gene family has been recently described during zebrafish ( Danio rerio ) embryogenesis, and primarily locates in the nervous system. Its most characterized member, RPRM , which duplicated to give rise rprma and rprmb in the fish lineage, is known to act as a tumor-suppressor gene in mammalian models. Here, we describe in detail the spatiotemporal expression of three rprm genes ( rprma, rprmb , and rprm l) within distinct anatomical structures in the developing peripheral and central nervous system. In the zebrafish, rprma mRNA is expressed in the olfactory placodes (OP) and olfactory epithelium (OE), rprmb is observed in the tectum opticum (TeO) and trigeminal ganglion (Tg), whereas rprml is found primarily in the telencephalon (Tel). At protein level, RPRM is present in a subset of cells in the OP, and neurons in the OE, TeO, hindbrain and sensory peripheral structures. Most importantly, the expression of RPRM has been conserved between teleosts and mammals. Thus, we provide a reference dataset describing the expression patterns of RPRM gene products during zebrafish and mouse development as a first step to approach the physiological role of the RPRM gene family.
- Published
- 2018
- Full Text
- View/download PDF
38. Expression Patterns of Extracellular Matrix Proteins during Posterior Commissure Development.
- Author
-
Stanic K, Saldivia N, Förstera B, Torrejón M, Montecinos H, and Caprile T
- Abstract
Extracellular matrix (ECM) molecules are pivotal for central nervous system (CNS) development, facilitating cell migration, axonal growth, myelination, dendritic spine formation, and synaptic plasticity, among other processes. During axon guidance, the ECM not only acts as a permissive or non-permissive substrate for navigating axons, but also modulates the effects of classical guidance cues, such as netrin or Eph/ephrin family members. Despite being highly important, little is known about the expression of ECM molecules during CNS development. Therefore, this study assessed the molecular expression patterns of tenascin, HNK-1, laminin, fibronectin, perlecan, decorin, and osteopontin along chick embryo prosomere 1 during posterior commissure development. The posterior commissure is the first transversal axonal tract of the embryonic vertebrate brain. Located in the dorso-caudal portion of prosomere 1, posterior commissure axons primarily arise from the neurons of basal pretectal nuclei that run dorsally to the roof plate midline, where some turn toward the ipsilateral side. Expressional analysis of ECM molecules in this area these revealed to be highly arranged, and molecule interactions with axon fascicles suggested involvement in processes other than structural support. In particular, tenascin and the HNK-1 epitope extended in ventro-dorsal columns and enclosed axons during navigation to the roof plate. Laminin and osteopontin were expressed in the midline, very close to axons that at this point must decide between extending to the contralateral side or turning to the ipsilateral side. Finally, fibronectin, decorin, and perlecan appeared unrelated to axonal pathfinding in this region and were instead restricted to the external limiting membrane. In summary, the present report provides evidence for an intricate expression of different extracellular molecules that may cooperate in guiding posterior commissure axons.
- Published
- 2016
- Full Text
- View/download PDF
39. Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.
- Author
-
Zwitter M, Rajer M, Stanic K, Vrankar M, Doma A, Cuderman A, Grmek M, Kern I, and Kovac V
- Subjects
- Adult, Aged, Carcinoma, Non-Small-Cell Lung enzymology, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Cisplatin administration & dosage, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Drug Administration Schedule, Erlotinib Hydrochloride administration & dosage, Female, Humans, Lung Neoplasms enzymology, Lung Neoplasms genetics, Lung Neoplasms pathology, Male, Middle Aged, Mutation, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, ErbB Receptors metabolism, Lung Neoplasms drug therapy
- Abstract
Among attempts to delay development of resistance to tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) with activating mutations of epidermal growth factor receptor (EGFR), intercalated therapy has not been properly evaluated. In a phase II trial, 38 patients with EGFR mutated NSCLC in advanced stage were treated with 4 to 6 3-weekly cycles of intercalated schedule with gemcitabine (1250 mg/m2, days 1 and 4), cisplatin (75 mg/m2, day 2) and erlotinib (150 mg, days 5 - 15), followed by continuous erlotinib as maintenance. In addition to standard radiologic evaluation according to RECIST, PET/CT was done prior to treatment and at 6 months, using PERCIST as a method for assessment of response. The primary endpoint was progression-free survival (PFS). In general, tolerance to treatment was good, even among 8 patients with performance status 2-3 and 13 patients with brain metastases; grade 4 toxicity included 2 cases of neutropenia and 4 thrombo-embolic events. Complete response (CR) or partial response (PR) were seen in 15 (39.5%) and 17 (44.7%) cases, respectively. All cases of CR were confirmed also by PET/CT. Median PFS was 23.4 months and median overall survival (OS) was 38.3 months. After a median follow-up of 35 months, 8 patients are still in CR and on maintenance erlotinib. In conclusion, intercalated treatment for treatment-naive patients with EGFR activating mutations leads to excellent response rate and prolonged PFS and survival. Comparison of the intercalated schedule to monotherapy with TKIs in a randomized trial is warranted.
- Published
- 2016
- Full Text
- View/download PDF
40. The role of cardiac computed tomography in diagnosing left ventricular noncompaction in patients with sinus node dysfunction.
- Author
-
Sustar A, Zagar D, Javoran D, Persic V, and Stanic K
- Subjects
- Adult, Cardiac Resynchronization Therapy Devices, Female, Humans, Male, Middle Aged, Sick Sinus Syndrome surgery, Tomography, X-Ray Computed methods, Isolated Noncompaction of the Ventricular Myocardium diagnostic imaging, Sick Sinus Syndrome diagnostic imaging
- Published
- 2016
- Full Text
- View/download PDF
41. Interaction between SCO-spondin and low density lipoproteins from embryonic cerebrospinal fluid modulates their roles in early neurogenesis.
- Author
-
Vera A, Recabal A, Saldivia N, Stanic K, Torrejón M, Montecinos H, and Caprile T
- Abstract
During early stages of development, encephalic vesicles are composed by a layer of neuroepithelial cells surrounding a central cavity filled with embryonic cerebrospinal fluid (eCSF). This fluid contains several morphogens that regulate proliferation and differentiation of neuroepithelial cells. One of these neurogenic factors is SCO-spondin, a giant protein secreted to the eCSF from early stages of development. Inhibition of this protein in vivo or in vitro drastically decreases the neurodifferentiation process. Other important neurogenic factors of the eCSF are low density lipoproteins (LDL), the depletion of which generates a 60% decrease in mesencephalic explant neurodifferentiation. The presence of several LDL receptor class A (LDLrA) domains (responsible for LDL binding in other proteins) in the SCO-spondin sequence suggests a possible interaction between both molecules. This possibility was analyzed using three different experimental approaches: (1) Bioinformatics analyses of the SCO-spondin region, that contains eight LDLrA domains in tandem, and of comparisons with the LDL receptor consensus sequence; (2) Analysis of the physical interactions of both molecules through immunohistochemical colocalization in embryonic chick brains and through the immunoprecipitation of LDL with anti-SCO-spondin antibodies; and (3) Analysis of functional interactions during the neurodifferentiation process when these molecules were added to a culture medium of mesencephalic explants. The results revealed that LDL and SCO-spondin interact to form a complex that diminishes the neurogenic capacities that both molecules have separately. Our work suggests that the eCSF is an active signaling center with a complex regulation system that allows for correct brain development.
- Published
- 2015
- Full Text
- View/download PDF
42. Complementary expression of EphA7 and SCO-spondin during posterior commissure development.
- Author
-
Stanic K, Vera A, González M, Recabal A, Astuya A, Torrejón M, Montecinos H, and Caprile T
- Abstract
Bilaterally symmetric organisms need to exchange information between the two sides of their bodies in order to integrate sensory inputs and coordinate motor control. This exchange occurs through commissures formed by neurons that project axons across the midline to the contralateral side of the central nervous system. The posterior commissure is the first transversal axonal tract of the embryonic vertebrate brain. It is located in the dorsal portion of the prosomere 1, at the caudal diencephalon. The axons of the posterior commissure principally come from neurons of ventrolateral and dorsolateral pretectal nuclei (parvocellular and magnocellular nucleus of the posterior commissure, respectively) that extend their axons toward the dorsal region. The trajectory of these axons can be divided into the following three stages: (1) dorsal axon extension towards the lateral roof plate; (2) fasciculation in the lateral roof plate; and (3) midline decision of turning to the ipsilateral side or continuing to the opposite side. The mechanisms and molecules that guide the axons during these steps are unknown. In the present work, immunohistochemical and in situ hybridization analyses were performed, with results suggesting the participation of EphA7 in guiding axons from the ventral to the dorsal region of the prosomere 1 through the generation of an axonal corridor limited by repulsive EphA7 walls. At the lateral roof plate, the axons became fasciculated in presence of SCO-spondin until reaching the midline. Finally, EphA7 expression was observed in the diencephalic midline roof plate, specifically in the region where some axons turn to the ipsilateral side, suggesting its participation in this decision. In summary, the present work proposes a mechanism of posterior commissure formation orchestrated by the complementary expression of the axon guidance cues SCO-spondin and EphA7.
- Published
- 2014
- Full Text
- View/download PDF
43. Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival.
- Author
-
Stanic K, Zwitter M, Hitij NT, Kern I, Sadikov A, and Cufer T
- Abstract
Background: The brain represents a frequent progression site in lung adenocarcinoma. This study was designed to analyse the association between the epidermal growth factor receptor (EGFR) mutation status and the frequency of brain metastases (BM) and survival in routine clinical practice., Patients and Methods: We retrospectively analysed the medical records of 629 patients with adenocarcinoma in Slovenia who were tested for EGFR mutations in order to analyse the cumulative incidence of BM, the time from the diagnosis to the development of BM (TDBM), the time from BM to death (TTD) and the median survival., Results: Out of 629 patients, 168 (27%) had BM, 90 patients already at the time of diagnosis. Additional 78 patients developed BM after a median interval of 14.3 months; 25.8 months in EGFR positive and 11.8 months in EGFR negative patients, respectively (p = 0.002). EGFR mutations were present in 47 (28%) patients with BM. The curves for cumulative incidence of BM in EGFR positive and negative patients demonstrate a trend for a higher incidence of BM in EGFR mutant patients at diagnosis (19% vs. 13%, p = 0.078), but no difference later during the course of the disease. The patients with BM at diagnosis had a statistically longer TTD (7.3 months) than patients who developed BM later (3.1 months). The TTD in EGFR positive patients with BM at diagnosis was longer than in EGFR negative patients (12.6 vs. 6.8, p = 0.005), while there was no impact of EGFR status on the TTD of patients who developed BM later., Conclusions: Except for a non-significant increase of frequency of BM at diagnosis in EGFR positive patients, EGFR status had no influence upon the cumulative incidence of BM. EGFR positive patients had a longer time to CNS progression. While EGFR positive patients with BM at diagnosis had a longer survival, EGFR status had no influence on TTD in patients who developed BM later during the course of disease.
- Published
- 2014
- Full Text
- View/download PDF
44. Subdivisions of chick diencephalic roof plate: implication in the formation of the posterior commissure.
- Author
-
Stanic K, Montecinos H, and Caprile T
- Subjects
- Animals, Chick Embryo, Electrophoresis, Polyacrylamide Gel, Immunohistochemistry, Integrin alpha6 metabolism, Intermediate Filament Proteins metabolism, Nerve Tissue Proteins metabolism, Nestin, Vimentin metabolism, Diencephalon embryology, Subcommissural Organ embryology
- Abstract
The subcommissural organ (SCO) is a roof plate differentiation located in the caudal diencephalon under the posterior commissure (PC). A role for SCO and its secretory product, SCO-spondin, in the formation of the PC has been proposed. Here, we provide immunohistochemical evidence to suggest that SCO is anatomically divided in a bilateral region positive for SCO-spondin that surrounds a negative medial region. Remarkably, axons contacting the lateral region are highly fasciculated, in sharp contrast with the defasciculated axons of the medial region. In addition, lateral axon fascicles run toward the midline inside of tunnels limited by the basal prolongations of SCO cells and extracellular SCO-spondin. Our in vitro data in collagen gel matrices show that SCO-spondin induces axonal growth and fasciculation of pretectal explants. Together, our findings support the idea that SCO-spondin participates in the guidance and fasciculation of axons of the PC.
- Published
- 2010
- Full Text
- View/download PDF
45. Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology Ljubljana.
- Author
-
Stanic K and Kovac V
- Abstract
Background: Prophylactic cranial irradiation (PCI) has been used in patients with small-cell lung cancer (SCLC) to reduce the incidence of brain metastases (BM) and thus increase overall survival. The aim of this retrospective study was to analyze the characteristics of patients with SCLC referred to the Institute of Oncology Ljubljana, their eligibility for PCI, patterns of dissemination, and survival., Patients and Methods: Medical charts of 357 patients with SCLC, referred to the Institute of Oncology Ljubljana between January 2004 and December 2006, were reviewed to determine characteristics of patients chosen for PCI. The following data were collected: age, gender, performance status (PS), extent of the disease, smoking status, type of primary treatment with outcome, haematological and biochemical parameters, PCI use, and finally brain metastases (BM) status at diagnoses and after treatment., Results: PCI was performed in 24 (6.7%) of all patients. Six (25%) patients developed brain metastases after they were treated with PCI. Brain was the only site of metastases in 4 patients, two progressed to multiple organs. Median overall survival of patients with PCI was 21.9 months, without PCI 12.13 months (p = 0.004). From the collected data there were good prognostic factors: age under 65 years, limited disease (LD), performance status, normal levels of lactate dehydrogenase (LDH) and normal levels of C-reactive protein levels (CRP). Other prognostic factors did not show statistical significant values., Conclusions: Survival of patients with LD, who have had PCI, was significantly better than those who had not. We decided to perform PCI in patients with LD, in those with complete or near complete response, and those with good performance status (≥ 80). We did not use PCI in extended disease (ED). The reason for that shall be addressed in the future. Doses for PCI were not uniform, therefore more standard approach should be considered.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.